Annual EBITDA
-$208.57 M
-$80.97 M-63.45%
December 31, 2024
Summary
- As of March 10, 2025, SYRE annual EBITDA is -$208.57 million, with the most recent change of -$80.97 million (-63.45%) on December 31, 2024.
- During the last 3 years, SYRE annual EBITDA has fallen by -$144.49 million (-225.51%).
- SYRE annual EBITDA is now -2247.39% below its all-time high of -$8.88 million, reached on December 1, 2014.
Performance
SYRE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$61.25 M
-$5.86 M-10.58%
December 31, 2024
Summary
- As of March 10, 2025, SYRE quarterly EBITDA is -$61.25 million, with the most recent change of -$5.86 million (-10.58%) on December 31, 2024.
- Over the past year, SYRE quarterly EBITDA has stayed the same.
- SYRE quarterly EBITDA is now -7055.72% below its all-time high of -$856.00 thousand, reached on March 1, 2014.
Performance
SYRE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$208.57 M
-$13.50 M-6.92%
December 31, 2024
Summary
- As of March 10, 2025, SYRE TTM EBITDA is -$208.57 million, with the most recent change of -$13.50 million (-6.92%) on December 31, 2024.
- Over the past year, SYRE TTM EBITDA has stayed the same.
- SYRE TTM EBITDA is now -24265.19% below its all-time high of -$856.00 thousand, reached on March 1, 2014.
Performance
SYRE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SYRE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -63.5% | 0.0% | 0.0% |
| 3 y3 years | -225.5% | -235.6% | -147.8% |
| 5 y5 years | -161.0% | -235.6% | -147.8% |
SYRE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -225.5% | at low | -235.6% | at low | -196.9% | at low |
| 5 y | 5-year | -225.5% | at low | -871.2% | at low | -225.5% | at low |
| alltime | all time | -2247.4% | at low | -7055.7% | at low | <-9999.0% | at low |
Spyre Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$208.57 M(+63.5%) | -$61.25 M(+10.6%) | -$208.57 M(+6.9%) |
| Sep 2024 | - | -$55.39 M(+25.5%) | -$195.07 M(+12.8%) |
| Jun 2024 | - | -$44.15 M(-7.6%) | -$172.92 M(+10.1%) |
| Mar 2024 | - | -$47.77 M(+0.0%) | -$157.12 M(+23.1%) |
| Dec 2023 | -$127.60 M(+54.1%) | -$47.75 M(+43.6%) | -$127.60 M(+29.5%) |
| Sep 2023 | - | -$33.24 M(+17.3%) | -$98.52 M(+17.9%) |
| Jun 2023 | - | -$28.34 M(+55.2%) | -$83.53 M(+8.4%) |
| Mar 2023 | - | -$18.26 M(-2.2%) | -$77.04 M(-7.0%) |
| Dec 2022 | -$82.82 M(+29.3%) | - | - |
| Dec 2022 | - | -$18.67 M(+2.3%) | -$82.82 M(-1.6%) |
| Sep 2022 | - | -$18.25 M(-16.5%) | -$84.18 M(-1.9%) |
| Jun 2022 | - | -$21.85 M(-9.1%) | -$85.80 M(+22.1%) |
| Mar 2022 | - | -$24.04 M(+20.0%) | -$70.26 M(+9.7%) |
| Dec 2021 | -$64.07 M(-20.4%) | -$20.03 M(+0.8%) | -$64.07 M(-3.6%) |
| Sep 2021 | - | -$19.88 M(+215.2%) | -$66.45 M(+3.1%) |
| Jun 2021 | - | -$6.31 M(-64.7%) | -$64.44 M(-18.9%) |
| Mar 2021 | - | -$17.85 M(-20.3%) | -$79.47 M(-1.3%) |
| Dec 2020 | -$80.48 M(+0.7%) | -$22.41 M(+25.4%) | -$80.48 M(+0.8%) |
| Sep 2020 | - | -$17.87 M(-16.2%) | -$79.88 M(-5.0%) |
| Jun 2020 | - | -$21.34 M(+13.1%) | -$84.05 M(+3.5%) |
| Mar 2020 | - | -$18.87 M(-13.5%) | -$81.23 M(+1.6%) |
| Dec 2019 | -$79.92 M | -$21.80 M(-1.1%) | -$79.92 M(+9.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$22.04 M(+19.0%) | -$73.35 M(+15.6%) |
| Jun 2019 | - | -$18.52 M(+5.5%) | -$63.47 M(+16.4%) |
| Mar 2019 | - | -$17.56 M(+15.3%) | -$54.55 M(+20.8%) |
| Dec 2018 | -$45.17 M(+64.7%) | -$15.23 M(+25.2%) | -$45.17 M(+23.8%) |
| Sep 2018 | - | -$12.17 M(+26.8%) | -$36.50 M(+13.1%) |
| Jun 2018 | - | -$9.60 M(+17.4%) | -$32.26 M(+10.0%) |
| Mar 2018 | - | -$8.18 M(+24.6%) | -$29.32 M(+6.9%) |
| Dec 2017 | -$27.43 M(+26.0%) | -$6.56 M(-17.3%) | -$27.43 M(+4.0%) |
| Sep 2017 | - | -$7.93 M(+19.1%) | -$26.37 M(+6.7%) |
| Jun 2017 | - | -$6.66 M(+6.0%) | -$24.71 M(+5.1%) |
| Mar 2017 | - | -$6.28 M(+14.0%) | -$23.52 M(+8.0%) |
| Dec 2016 | -$21.77 M(+94.0%) | -$5.51 M(-12.1%) | -$21.77 M(+7.6%) |
| Sep 2016 | - | -$6.27 M(+14.7%) | -$20.23 M(+16.6%) |
| Jun 2016 | - | -$5.46 M(+20.4%) | -$17.36 M(+30.4%) |
| Mar 2016 | - | -$4.54 M(+14.4%) | -$13.31 M(+18.6%) |
| Dec 2015 | -$11.23 M(+26.3%) | -$3.97 M(+17.0%) | -$11.23 M(+7.7%) |
| Sep 2015 | - | -$3.39 M(+139.9%) | -$10.43 M(+2.5%) |
| Jun 2015 | - | -$1.41 M(-42.3%) | -$10.17 M(-3.0%) |
| Mar 2015 | - | -$2.45 M(-22.6%) | -$10.48 M(+18.0%) |
| Dec 2014 | -$8.88 M | -$3.17 M(+1.1%) | -$8.88 M(+55.4%) |
| Sep 2014 | - | -$3.13 M(+81.7%) | -$5.72 M(+121.5%) |
| Jun 2014 | - | -$1.73 M(+101.5%) | -$2.58 M(+201.5%) |
| Mar 2014 | - | -$856.00 K | -$856.00 K |
FAQ
- What is Spyre Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Spyre Therapeutics?
- What is Spyre Therapeutics annual EBITDA year-on-year change?
- What is Spyre Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly EBITDA year-on-year change?
- What is Spyre Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Spyre Therapeutics?
- What is Spyre Therapeutics TTM EBITDA year-on-year change?
What is Spyre Therapeutics annual EBITDA?
The current annual EBITDA of SYRE is -$208.57 M
What is the all time high annual EBITDA for Spyre Therapeutics?
Spyre Therapeutics all-time high annual EBITDA is -$8.88 M
What is Spyre Therapeutics annual EBITDA year-on-year change?
Over the past year, SYRE annual EBITDA has changed by -$80.97 M (-63.45%)
What is Spyre Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SYRE is -$61.25 M
What is the all time high quarterly EBITDA for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly EBITDA is -$856.00 K
What is Spyre Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SYRE quarterly EBITDA has changed by $0.00 (0.00%)
What is Spyre Therapeutics TTM EBITDA?
The current TTM EBITDA of SYRE is -$208.57 M
What is the all time high TTM EBITDA for Spyre Therapeutics?
Spyre Therapeutics all-time high TTM EBITDA is -$856.00 K
What is Spyre Therapeutics TTM EBITDA year-on-year change?
Over the past year, SYRE TTM EBITDA has changed by $0.00 (0.00%)